vs

Side-by-side financial comparison of PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) and PARKE BANCORP, INC. (PKBK). Click either name above to swap in a different company.

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. is the larger business by last-quarter revenue ($44.6M vs $22.7M, roughly 2.0× PARKE BANCORP, INC.). PARKE BANCORP, INC. runs the higher net margin — 48.8% vs -90.4%, a 139.2% gap on every dollar of revenue. On growth, PARKE BANCORP, INC. posted the faster year-over-year revenue change (35.7% vs 13.8%). PARKE BANCORP, INC. produced more free cash flow last quarter ($39.0M vs $-19.9M). Over the past eight quarters, PARKE BANCORP, INC.'s revenue compounded faster (22.6% CAGR vs 7.3%).

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

Parke Bancorp, Inc. is a U.S. regional bank holding company operating Parke Bank. It offers commercial and retail banking services including deposit products, mortgage loans, small business financing and personal lending, primarily serving customers across New Jersey and the Philadelphia metropolitan area.

PACB vs PKBK — Head-to-Head

Bigger by revenue
PACB
PACB
2.0× larger
PACB
$44.6M
$22.7M
PKBK
Growing faster (revenue YoY)
PKBK
PKBK
+21.9% gap
PKBK
35.7%
13.8%
PACB
Higher net margin
PKBK
PKBK
139.2% more per $
PKBK
48.8%
-90.4%
PACB
More free cash flow
PKBK
PKBK
$58.9M more FCF
PKBK
$39.0M
$-19.9M
PACB
Faster 2-yr revenue CAGR
PKBK
PKBK
Annualised
PKBK
22.6%
7.3%
PACB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PACB
PACB
PKBK
PKBK
Revenue
$44.6M
$22.7M
Net Profit
$-40.4M
$11.1M
Gross Margin
37.1%
Operating Margin
-92.3%
64.2%
Net Margin
-90.4%
48.8%
Revenue YoY
13.8%
35.7%
Net Profit YoY
-1802.7%
49.8%
EPS (diluted)
$-0.11
$0.93

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PACB
PACB
PKBK
PKBK
Q4 25
$44.6M
$22.7M
Q3 25
$38.4M
$21.0M
Q2 25
$39.8M
$18.7M
Q1 25
$37.2M
$17.4M
Q4 24
$39.2M
$16.8M
Q3 24
$40.0M
$15.6M
Q2 24
$36.0M
$15.5M
Q1 24
$38.8M
$15.1M
Net Profit
PACB
PACB
PKBK
PKBK
Q4 25
$-40.4M
$11.1M
Q3 25
$-38.0M
$10.6M
Q2 25
$-41.9M
$8.3M
Q1 25
$-426.1M
$7.8M
Q4 24
$2.4M
$7.4M
Q3 24
$-60.7M
$7.5M
Q2 24
$-173.3M
$6.5M
Q1 24
$-78.2M
$6.2M
Gross Margin
PACB
PACB
PKBK
PKBK
Q4 25
37.1%
Q3 25
41.4%
Q2 25
36.9%
Q1 25
-3.7%
Q4 24
25.6%
Q3 24
25.0%
Q2 24
16.5%
Q1 24
29.1%
Operating Margin
PACB
PACB
PKBK
PKBK
Q4 25
-92.3%
64.2%
Q3 25
-101.1%
64.2%
Q2 25
-112.8%
59.0%
Q1 25
-1154.5%
59.1%
Q4 24
-390.1%
58.0%
Q3 24
-160.3%
60.2%
Q2 24
-488.3%
56.7%
Q1 24
-209.6%
55.4%
Net Margin
PACB
PACB
PKBK
PKBK
Q4 25
-90.4%
48.8%
Q3 25
-98.9%
50.6%
Q2 25
-105.4%
44.3%
Q1 25
-1146.8%
44.6%
Q4 24
6.0%
44.2%
Q3 24
-151.9%
48.1%
Q2 24
-481.3%
41.6%
Q1 24
-201.4%
40.7%
EPS (diluted)
PACB
PACB
PKBK
PKBK
Q4 25
$-0.11
$0.93
Q3 25
$-0.13
$0.89
Q2 25
$-0.14
$0.69
Q1 25
$-1.44
$0.65
Q4 24
$-0.44
$0.61
Q3 24
$-0.22
$0.62
Q2 24
$-0.64
$0.53
Q1 24
$-0.29
$0.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PACB
PACB
PKBK
PKBK
Cash + ST InvestmentsLiquidity on hand
$279.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$5.3M
$324.5M
Total Assets
$784.1M
$2.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PACB
PACB
PKBK
PKBK
Q4 25
$279.5M
Q3 25
$298.7M
Q2 25
$314.7M
Q1 25
$343.1M
Q4 24
$389.9M
Q3 24
$471.1M
Q2 24
$509.8M
Q1 24
$561.9M
Stockholders' Equity
PACB
PACB
PKBK
PKBK
Q4 25
$5.3M
$324.5M
Q3 25
$36.1M
$314.8M
Q2 25
$61.5M
$312.2M
Q1 25
$91.6M
$305.9M
Q4 24
$506.6M
$300.1M
Q3 24
$453.1M
$296.5M
Q2 24
$492.7M
$292.8M
Q1 24
$649.0M
$288.4M
Total Assets
PACB
PACB
PKBK
PKBK
Q4 25
$784.1M
$2.2B
Q3 25
$803.2M
$2.2B
Q2 25
$825.5M
$2.2B
Q1 25
$860.8M
$2.1B
Q4 24
$1.3B
$2.1B
Q3 24
$1.5B
$2.1B
Q2 24
$1.5B
$2.0B
Q1 24
$1.7B
$2.0B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PACB
PACB
PKBK
PKBK
Operating Cash FlowLast quarter
$-19.1M
$39.6M
Free Cash FlowOCF − Capex
$-19.9M
$39.0M
FCF MarginFCF / Revenue
-44.6%
171.3%
Capex IntensityCapex / Revenue
1.9%
2.6%
Cash ConversionOCF / Net Profit
3.57×
TTM Free Cash FlowTrailing 4 quarters
$-114.1M
$63.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PACB
PACB
PKBK
PKBK
Q4 25
$-19.1M
$39.6M
Q3 25
$-18.7M
$11.4M
Q2 25
$-29.4M
$6.8M
Q1 25
$-44.1M
$7.0M
Q4 24
$-30.6M
$35.2M
Q3 24
$-45.5M
$9.4M
Q2 24
$-54.3M
$8.9M
Q1 24
$-75.7M
$8.3M
Free Cash Flow
PACB
PACB
PKBK
PKBK
Q4 25
$-19.9M
$39.0M
Q3 25
$-18.8M
$11.2M
Q2 25
$-29.9M
$6.7M
Q1 25
$-45.4M
$6.6M
Q4 24
$-32.3M
$35.0M
Q3 24
$-46.3M
$9.4M
Q2 24
$-55.7M
$8.9M
Q1 24
$-79.6M
$8.3M
FCF Margin
PACB
PACB
PKBK
PKBK
Q4 25
-44.6%
171.3%
Q3 25
-48.9%
53.5%
Q2 25
-75.3%
35.8%
Q1 25
-122.3%
38.0%
Q4 24
-82.3%
209.1%
Q3 24
-115.7%
60.0%
Q2 24
-154.8%
57.1%
Q1 24
-205.0%
55.1%
Capex Intensity
PACB
PACB
PKBK
PKBK
Q4 25
1.9%
2.6%
Q3 25
0.2%
0.5%
Q2 25
1.4%
0.3%
Q1 25
3.7%
2.2%
Q4 24
4.1%
0.7%
Q3 24
2.0%
0.1%
Q2 24
4.1%
0.2%
Q1 24
10.0%
0.1%
Cash Conversion
PACB
PACB
PKBK
PKBK
Q4 25
3.57×
Q3 25
1.07×
Q2 25
0.82×
Q1 25
0.90×
Q4 24
-12.93×
4.75×
Q3 24
1.25×
Q2 24
1.38×
Q1 24
1.36×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PACB
PACB

Products$39.0M87%
Service And Other$5.7M13%

PKBK
PKBK

Segment breakdown not available.

Related Comparisons